{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/delirium/management/covid-19/","result":{"pageContext":{"chapter":{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field 61050b50-2eca-47b7-9caa-ab9500b4f3ca --><h2>Scenario: COVID-19 Management</h2><!-- end field 61050b50-2eca-47b7-9caa-ab9500b4f3ca -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item 9ee8d81c-004a-4ed2-9056-ab9500b4f392 --><!-- begin field 28286859-6526-497e-947a-acbc01579011 --><p>From age 18 years onwards.</p><!-- end field 28286859-6526-497e-947a-acbc01579011 --><!-- end item 9ee8d81c-004a-4ed2-9056-ab9500b4f392 -->","topic":{"id":"6b89f111-d1d1-510e-8846-71e15c389f06","topicId":"64430de8-33e7-409d-b433-725a712a6f41","topicName":"Delirium","slug":"delirium","lastRevised":"Last revised in April 2020","chapters":[{"id":"0455d257-6ef6-5e50-9dc0-21780666b8e7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a71db69b-5a97-544a-a806-ec82704f3907","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"58e84228-4844-5721-859b-91d58faa7eb6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"999affe9-788e-52a9-83c8-ad933103eeb5","slug":"changes","fullItemName":"Changes"},{"id":"29c67640-566b-5fa4-8966-5b08ca667756","slug":"update","fullItemName":"Update"}]},{"id":"6dddaa0e-c24c-5f4e-8044-6a3229f859df","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7e8bf385-fd9a-544a-bc9d-375555c17ab0","slug":"goals","fullItemName":"Goals"},{"id":"8f18311c-4fad-5969-8a94-addcca05fb64","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b45b0c3d-03c0-5300-b0c4-62ccd106e229","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7b7d4906-4705-52ba-a39f-ecfb7c5d1e98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"331ceb18-88fc-530e-aa48-bae28dde9901","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"558ba6d3-06ab-5370-b6b7-09548f2c3c8e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"b6e24e45-958a-5052-800a-ef5c6f140719","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2b925b35-d493-5d01-bb58-9f18c37e1357","slug":"definition","fullItemName":"Definition"},{"id":"27bd26a5-66e1-5d51-a992-7e06e6a3cdfa","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"c3582ffa-e505-5580-a3fa-f6a04f0938cc","slug":"precipitating-factors","fullItemName":"Precipitating factors"},{"id":"44402d85-ef9c-562b-ad2c-e99c0d8c60a7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"799dcaa5-4683-5bf0-a9d7-dfc860ab7c81","slug":"complications","fullItemName":"Complications"},{"id":"ca4b25bd-2486-55a7-92c0-c39322caa272","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"993580f3-4201-5dd5-8a6d-f64de509d328","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3f7d0746-b45f-5f52-8e49-7effac5e3547","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f84af6b7-85fc-56aa-9554-29d1231a7fd1","slug":"assessment","fullItemName":"Assessment"},{"id":"cc3618cd-d41e-5719-939a-78ed0be305e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","fullItemName":"Management","slug":"management","subChapters":[{"id":"81f2aa66-ed46-54f0-80b5-4dfca4afb344","slug":"management","fullItemName":"Scenario: Management"},{"id":"58bb812f-7b3c-57be-aab1-8ae228aff1d1","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"769a3265-9e21-5508-b937-bf6aa4a8f378","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"fa09afb1-cc68-5f68-afbe-7486c91a5ed4","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"4faac93d-8b62-5294-933f-214a1155f283","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"c02516c6-89cb-5dc3-99db-17f261f5f80e","slug":"levomepromazine","fullItemName":"Levomepromazine"}]},{"id":"cd438911-3d3a-51dd-8455-3e41c260dd60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cec2028c-5183-50fb-9bb7-f20aea64a152","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a5323429-af72-5d8b-a251-0715c1a15bba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"26c6273a-60c7-5b9a-b49f-9f9fbb623941","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b70aed75-14ce-57f4-b2b0-474fa4480d56","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c5faba8c-4118-59d9-af20-8c8d52a89eb2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"71e02a81-885f-515f-8852-109bc9b5580f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"51d66a08-1fc6-5593-8764-c9d4e547d827","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9d04a09f-9612-570d-aeb7-c0121bda09c4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d801307f-dbb5-52a2-9a1f-1afe6056c9c6","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 712ed6ff-1a85-4b9f-b4cf-ab9500b4f3cc --><h3>How should my management vary when considering the possibility of COVID-19? </h3><!-- end field 712ed6ff-1a85-4b9f-b4cf-ab9500b4f3cc -->","summary":null,"htmlStringContent":"<!-- begin item 6576ae0d-66bf-4e4d-b96b-ab9500b4f3cc --><!-- begin field b95d09bb-64cb-47cf-b289-ab9500b4f3cc --><ul><li class=\"MsoNormal\">People in the palliative phase of their illness and who may have contracted COVID-19 are at higher risk of developing anxiety, delirium, and agitation.</li><li class=\"MsoNormal\">Assess and treat reversible causes of anxiety or delirium, with or without agitation, these can include hypoxia (which is common in severe COVID-19 infections, urinary retention and constipation).</li><li class=\"MsoNormal\">Consider trying a benzodiazepine to manage anxiety or agitation (see Table 1 for treatments for managing anxiety, delirium, and agitation).</li></ul><p class=\"MsoNormal\"><strong>Table 1. </strong>Treatments for managing anxiety, delirium, and agitation in people aged 18 years and over.</p><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse: collapse; width: 100%; height: 864px; border-color: initial; border-style: none;\" width=\"100%\"><thead><tr style=\"mso-yfti-irow: 1;\"><td style=\"border: 1pt inset #999999; padding: 9pt; height: 52px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Treatment</strong></p></td><td style=\"border-top: 1pt inset #999999; border-right: 1pt inset #999999; border-bottom: 1pt inset #999999; border-image: initial; border-left: none; padding: 9pt; height: 52px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Dosage</strong></p></td></tr></thead><tbody><tr style=\"mso-yfti-irow: 2;\"><td style=\"border-right: 1pt inset #999999; border-bottom: 1pt inset #999999; border-left: 1pt inset #999999; border-image: initial; border-top: none; padding: 9pt; height: 129px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Anxiety or agitation and able to swallow:</strong> lorazepam tablets</p></td><td style=\"border-top: none; border-left: none; border-bottom: 1pt inset #999999; border-right: 1pt inset #999999; padding: 9pt; height: 129px;\" valign=\"top\"><p class=\"MsoNormal\">Lorazepam 0.5 mg to 1 mg four times a day as required (maximum 4 mg in 24 hours).</p><p class=\"MsoNormal\">Reduce the dose to 0.25 mg to 0.5 mg in elderly or debilitated people (maximum 2 mg in 24 hours).</p><p class=\"MsoNormal\">Oral tablets can be used sublingually (note this is an off-label use).</p></td></tr><tr style=\"mso-yfti-irow: 3;\"><td style=\"border-right: 1pt inset #999999; border-bottom: 1pt inset #999999; border-left: 1pt inset #999999; border-image: initial; border-top: none; padding: 9pt; height: 151px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Anxiety or agitation and unable to swallow:</strong> midazolam injection</p></td><td style=\"border-top: none; border-left: none; border-bottom: 1pt inset #999999; border-right: 1pt inset #999999; padding: 9pt; height: 151px;\" valign=\"top\"><p class=\"MsoNormal\">Midazolam 2.5 mg to 5 mg subcutaneously every 2–4 hours as required.</p><p class=\"MsoNormal\">If needed frequently (more than twice daily), a subcutaneous infusion via a syringe driver may be considered (if available) starting with midazolam 10 mg over 24 hours.</p><p class=\"MsoNormal\">Reduce dose to 5 mg over 24 hours if estimated glomerular filtration rate (eGFR) is less than 30 ml per minute.</p></td></tr><tr style=\"mso-yfti-irow: 4;\"><td style=\"border-right: 1pt inset #999999; border-bottom: 1pt inset #999999; border-left: 1pt inset #999999; border-image: initial; border-top: none; padding: 9pt; height: 255px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Delirium and able to swallow:</strong> haloperidol tablets</p></td><td style=\"border-top: none; border-left: none; border-bottom: 1pt inset #999999; border-right: 1pt inset #999999; padding: 9pt; height: 255px;\" valign=\"top\"><p class=\"MsoNormal\">Haloperidol 0.5 mg to 1 mg at night and every 2 hours when required. Increase dose in 0.5 mg to 1 mg increments as required (maximum 10 mg daily, or 5 mg daily in elderly people).</p><p class=\"MsoNormal\">The same dose of haloperidol may be administered subcutaneously as required rather than orally, or a subcutaneous infusion of 2.5 mg to 10 mg over 24 hours.</p><p class=\"MsoNormal\">Consider a higher starting dose (1.5 mg to 3 mg) if the person is severely distressed or causing immediate danger to others.</p><p class=\"MsoNormal\">Consider adding a benzodiazepine such as lorazepam or midazolam if the person remains agitated (see dosages above).</p></td></tr><tr style=\"mso-yfti-irow: 5; mso-yfti-lastrow: yes;\"><td style=\"border-right: 1pt inset #999999; border-bottom: 1pt inset #999999; border-left: 1pt inset #999999; border-image: initial; border-top: none; padding: 9pt; height: 173px;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Delirium and unable to swallow:</strong> levomepromazine injection</p></td><td style=\"border-top: none; border-left: none; border-bottom: 1pt inset #999999; border-right: 1pt inset #999999; padding: 9pt; height: 173px;\" valign=\"top\"><p class=\"MsoNormal\">Levomepromazine 12.5 mg to 25 mg subcutaneously as a starting dose and then hourly as required (use 6.25 mg to 12.5 mg in the elderly).</p><p class=\"MsoNormal\">Maintain with subcutaneous infusion of 50 mg to 200 mg over 24 hours, increased according to response (doses greater than 100 mg over 24 hours should be given under specialist supervision).</p><p class=\"MsoNormal\">Consider midazolam alone or in combination with levomepromazine if the person is also anxious (see dosages above).</p></td></tr></tbody></table><p class=\"MsoNormal\"><em>Note:</em> At the time of publication (April 2020), midazolam and levomepromazine do not have a UK marketing authorisation for this indication or route of administration.</p><ul><li class=\"MsoNormal\">NICE advises that you should seek specialist advice for people aged under 18 years.</li></ul><!-- end field b95d09bb-64cb-47cf-b289-ab9500b4f3cc --><!-- end item 6576ae0d-66bf-4e4d-b96b-ab9500b4f3cc -->","subChapters":[{"id":"d6c894c7-c251-562c-9efb-e23b5f4c60bc","slug":"basis-for-recommendation-88a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 146ef889-4ceb-42da-a2bb-ab9500b4f3ce --><h4>Basis for recommendation</h4><!-- end field 146ef889-4ceb-42da-a2bb-ab9500b4f3ce -->","summary":null,"htmlStringContent":"<!-- begin item 88a3a0d3-29c9-42ae-bf86-ab9500b4f3ce --><!-- begin field 30c29e10-1b1b-4821-8254-ab9500b4f3ce --><p class=\"MsoNormal\">These recommendations are based on National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/delirium/references/\">NICE, 2020</a>].</p><!-- end field 30c29e10-1b1b-4821-8254-ab9500b4f3ce --><!-- end item 88a3a0d3-29c9-42ae-bf86-ab9500b4f3ce -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}